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Study objectives: The process of intermittent hypoxia-reoxygenation produces airway inflam-
mation and endothelial dysfunction that favors the development of cardiovascular disorders in
obstructive sleep apnea syndrome (OSAS). Nitric oxide (NO) is an important mediator in airway
inflammation and the regulation of endothelium-dependent vasodilation.
Design: This study compared airway NO (FENO) and alveolar NO (CANO) measurements in exhaled
breath in 30 OSAS patients to those of 30 healthy (non-OSAS) individuals and determined the
relationship between NO levels and OSAS severity. Additionally, NO measurements were
analyzed after 3 months of CPAP treatment.
Measurements and results: The mean (SD) FENO level in the OSAS group (27.2  18 ppb) was
higher than in the healthy non-OSAS group (p Z 0.006). The mean CANO level was
1.65  0.90 ppb, lower than in the non-OSAS group (p Z 0.001). A significant correlation
was found between FENO and CANO levels and the apneaehypopnea index (AHI) in the OSAS
group (r Z 0.8, p < 0.05; r Z 0.9, p Z 0.01, respectively). FENO levels decreased and CANO
levels increased significantly after CPAP treatment.
Conclusions: Severe OSAS patients have higher FENO and lower CANO levels and these are
restored to normal after CPAP treatment, reflecting the correction of local upper airway
inflammation and endothelial dysfunction present in OSAS patients. Exhaled breath techniques
can be useful to identify airway inflammation and endothelial dysfunction in severe OSAS
patients.
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Airway and alveolar nitric oxide measurements 631Introduction MethodsIn obstructive sleep apnea syndrome (OSAS), a highly
prevalent disease affecting 4% and 2% of adult males and
females, respectively,1 recurrent upper airway obstructive
episodes cause intermittent arterial oxygen desaturation,
nocturnal arousals and disruption of sleep architecture.2
OSAS is a cardiovascular risk factor3,4 associated with
increased morbidity and mortality,3,5 one whose multifac-
torial pathogenesis involves metabolic and autonomic dys-
regulation, inflammatory processes and oxidative stress.4,6
In OSAS patients intermittent hypoxia-reoxygenation
episodes provide the mechanism by which inflammatory
mediators are released, triggering the upper airway and
systemic inflammation described in these patients.4,6 The
upper airway inflammation, aggravated by mechanical
injury caused by repeated pharyngeal collapse, increases
the airway obstruction. Moreover, the systemic inflamma-
tory process also increases the release of oxygen-free
radicals beyond the physiologic antioxidant capacity,
generating oxidative stress.7e9 This encourages endothelial
dysfunction and provides a favorable environment for
cardiovascular disorders such as systemic hypertension and
stroke.10,11
Nitric oxide (NO) is implicated in the presence of airway
inflammation in several respiratory diseases when it is
synthesized in airway cells by the inducible NO synthase
enzyme.12 NO is also an oxygen-free radical and a powerful
vasodilator released by endothelial NO synthase, involved in
platelet aggregation and the regulation of vascular tone.
Several studies have demonstrated a decrease in circulating
NO in OSAS patients.13 Techniques for the measurement of
exhaled breath NO offer noninvasive, reliable and easy ways
to assess upper airway and bronchial inflammation bymeans
of the fraction of NO in the airway compartment (FENO).
14
These exhaled breath techniques are also useful to
measure the NO concentration in the alveolar compartment
(CANO), which indirectly marks pathogenic changes in the
distal airways and alveolar-capillary membrane, thereby
reflecting endothelial dysfunction.15 The FENO levels repor-
ted for OSAS patients have been inconsistent in the litera-
ture, with elevated concentrations observed by some
authors16,17 but not by others.18 CANO levels in OSAS patients
have not usually been investigated, although one recent
study measured this parameter before and after only two
nights of continuous positive airway pressure (CPAP).18
CPAP is described as the treatment of choice for severe
OSAS,19 yet we still lack an objective criterion to determine
whether to treat OSAS patients without symptoms or known
cardiovascular factors. Nor do we know whether early CPAP
treatment would prevent future cardiovascular diseases in
these patients.20
The use of simple, noninvasive measurements would be
useful to better understand OSAS pathophysiology and to
identify important interindividual differences in disorder’s
consequences. Starting with the hypothesis that FENO and
CANO are candidate noninvasive measures for use in this
setting, we aimed to determine FENO and CANO levels in
a group of OSAS patients before and after 3 months of
treatment with CPAP to evaluate the relation between each
measure of NO and OSAS severity and response to treatment.Subjects
Consecutive patients meeting the inclusion criteria were
recruited for this prospective study. All had been referred
to our sleep-disorderedebreathing clinic because of clinical
symptoms suggestive of OSAS. Patients whose test results
confirmed this disease were included in an OSAS group.
Healthy individuals in whom OSAS was ruled out were
recruited for a non-OSAS group in which to determine
physiologic levels of FENO and CANO.
We excluded patients with a history of cognitive disor-
ders, symptoms of respiratory tract infection in the 6
weeks prior to referral, and atopy or respiratory disease
that might affect FENO levels (asthma, chronic obstructive
pulmonary disease, sarcoidosis, lung cancer, bronchiec-
tasis, cystic fibrosis) or kidney, liver and rheumatic
diseases. Patients were also excluded if they had received
treatment with inhaled or oral corticosteroids in the last
four weeks or if spirometry results indicated loss of lung
function.
The study was approved by the ethics committee of our
hospital and all subjects (both patients and healthy indi-
viduals) gave their signed, informed consent.Study design
Individual characteristics were recorded and a clinical ques-
tionnaire was used to collect information on smoking, medi-
cation, cardiovascular disease (hypertension, ischaemic
heart disease, and stroke), diabetes mellitus and dyslipide-
mia. Excessive daytime sleepiness was assessed using the
Epworth Sleepiness Scale.21 Complete physical examinations
(including a chest x-ray for patients) and lung function tests
(spirometry and a bronchodilator test), were also given. All
individuals were studied by overnight respiratory polygraphy
or polysomnography. Trained staff assigned to our lung func-
tion laboratory and sleep-disorderedebreathing unit carried
out the tests.
Patients were included in the OSAS group consecutively
if the results of the sleep study indicated they had an
apneaehypopnea index (AHI)  15. Healthy (non-OSAS)
group individuals were found to have an AHI < 5. Within 5
days of each sleep study, each subject underwent FENO
and CANO measurement procedures, all of which were
carried out at the same hour of the day (of 09:00 to 11:00
a.m.), before spirometry, so as not to interfere with that
test.
OSAS patients who met the criteria for CPAP treatment2
also underwent a titration night study by attended poly-
somnography or with a simplified automatic CPAP device
(AutoSet Clinical System, Resmed, North Ryde,
Australia).22 After 3 months of CPAP treatment the patient
came to a follow-up visit that included an interview and
collection of anthropometric data as well as the proce-
dures needed for determining FENO and CANO. CPAP treat-
ment adherence was assessed objectively by reading the
counter that showed the operating hours since treatment
was started.
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Polysomnography
The OSAS diagnosis was established by overnight poly-
somnography (Siesta, Compumedics, Melbourne, Australia)
in those patients who had excessive daytime sleepiness and/
or associated comorbidity.2 Sleep stages were documented
by two electroencephalography and two electrooculography
channels, submental and anterior tibial electromyography
channels. Arterial oxygen saturation was assessed by pulse
oximetry (SpO2) and airflow by nasal flow pressure sensor
and oronasal thermistor; thoracic and abdominal excursion
bands, electrocardiographic leads, and snoring and body
position sensors were also in place. Recordings were made
for a minimum of 6 h, with a minimum sleep time of 3 h.
Apnea was defined as the absence of airflow for 10 s and
hypopnea as a 30%e90% reduction of airflow compared with
baseline lasting 10 s in combination with a reduction of
3% in SpO2 and/or followed by an arousal.23,24 We recor-
ded the mean AHI, as the average total number of apneic
and hypopneic events per sleep hour, the number of
arousals, the arousal index (number of arousals per hour),
the mean SpO2 and the cumulative time with SpO2 < 90%
expressed as a percentage of total sleep time registered
(CT90%). No sleep studies had to be repeated.23
Respiratory polygraphy
The remaining subjects, who had not reported excessive
sleepiness or comorbidity, underwent respiratory polyg-
raphy (Sibelhome 300, Sibel, Barcelona, Spain). SpO2 was
assessed by pulse oximetry and airflow by nasal flow pres-
sure sensor and oronasal thermistor. Thoracic and abdom-
inal excursion bands and snoring and body position sensors
were also in position. The same AHI criteria used in poly-
somnography were also used in polygraphy, with the
exception that arousals were not detected by the polyg-
raphy device.25
Lung function
Spirometry and bronchodilator tests (Datospir 120, Sibel)
were performed before and after inhalation of salbutamol
following international guidelines.26 A forced expiratory
volume in 1 s (FEV1)  80% of predicted and/or a ratio of
FEV1 to forced vital capacity (FVC)  75% were considered
to lie within normal limits in this clinical setting. Patients
who presented spirometric values below these cutoffs were
excluded. Spirometry was repeated after exhaled NO
measurement 3 months after the beginning of CPAP treat-
ment in the OSAS patient group.
NO measurements
FENO measurement: the single-breath technique
FENO was measured with a conventional chemo-
luminescence analyser (NIOX, Aerocrine AB, Stockholm,
Sweden) using the on-line standardized single-breath
technique according to international guidelines.27 The
subject inhaled to total lung capacity from the device once
and then exhaled at a constant flow rate (VE) of 50 mL/s forapproximately 10 s. Resistance at a pressure above
5e20 cm H2O was provided to ensure velum closure and
exclude contamination from nasal NO. To interpret FENO
recordings we considered valid only the NO plateau of the
exhalation curve (held for >3 s and with a variation <10%).
The mean value of FENO from 3 technically valid measure-
ments was recorded.
CANO measurement: the multiple flow rate
exhalation technique
The patient exhaled at several different VE (10, 30, 100 and
200 mL/s) using the standard on-line technique, according
a previously validated method.28 The NO levels for each
exhaled flow rate (VNO) in picoliters per second were stored
and analyzed on the computer using NO analysis software.
To calculate the flow-independent parameters required,
we introduced the values for 100 and 200 mL/s into the
equations of Tsoukias and Silkoff.28 By this means, we were
able to derive the positive slope of the relationship
between VNO and VE, which represents CANO, and the
intercept, which is the maximum total airway NO flow
(J’AW,NO). Airway diffusion (DAWNO) of NO was calculated
using the Silkoff equation (DAWNO Z J’AWNO  CANO).29
Statistical analyses
To express the results of quantitative variables we used
means  SD. Results for categorical variables are reported
as absolute frequencies and percentages. The t test was
used to compare the means of independent paired vari-
ables. The Pearson correlation coefficient was used to
assess the correlation between FENO and CANO measure-
ments with sleep study variables which reflect severity of
disease (AHI, SpO2, CT90%), as the dataset for the sample
presented a normal distribution (according to the Kolmor-
ogoveSmirnov test). Additionally, age, sex, weight and
body mass index (BMI) were entered into a multiple logistic
regression model to evaluate whether the relationship
between FENO and CANO level and the AHI´ was maintained
after correction for covariation. A p-value <0.05 was
considered statistically significant. An independent statis-
tician analyzed the raw data, using the SPSS statistical
package (version 14) (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics and sleep study results
The functional, clinical and anthropometric characteristics
of both groups are described in Table 1. The mean AHI was
46.7  18.0 for OSAS patients and 2.4  1.7 for non-OSAS
subjects (pZ 0.001). The mean nighttime SpO2 was 93  2%
for OSAS patients and 96  1.1 for non-OSAS subjects
(p Z 0.001).
Of 39 patients with a sleep study confirming the diag-
nosis of OSAS, 9 were excluded from the study because they
did not perform the multiple flow rate exhalation tech-
nique successfully. Thirty patients whose sleep study did
not confirm the diagnosis made up the healthy (non-OSAS)
Table 1 Group characteristics of OSAS and healthy (non-OSAS) patients.
OSAS group n Z 30 Healthy Non-OSAS group n Z 30 p-value
Age, yrs 54  10 40.7  10 0.001
Sex, male/female 22/8 14/16 0.001
BMI kg/m2 31.16  3.34 24.8  2.8 0.001
FEV1% pred 101  11 107  13 0.13
FVC % pred 97  11 104  10 0.14
FEV1/FVC % 79  4 80  6 0.75
Smoking, n 0.001
Smoker 6 2
Non-smokers 9 1
Ex-smoker 15 27
Hypertension, n (%) 13 (43) 3 (10) 0.007
Diabetes mellitus, n (%) 4 (13) 0 (0) 0.005
Dyslipidemia, n 5 (16) 1 (3) 0.008
Ischemic heart disease, n 1 (3) 0 (0) 0.001
Stroke, n 0 (0) 0 (0) 0.1
Epworth scale 13  4.3 9.8  3.2 0.04
Data are presented as mean  SD, unless otherwise noted.
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polygraphy.
NO measurements at diagnosis
The mean FENO levels were significantly higher in the OSAS
group than in the healthy (non-OSAS) group (Table 2). A
significant correlation was found between FENO and AHI
(r Z 0.8; p < 0.05). Mean nighttime SpO2 (r Z 0.4;
p Z 0.01), and CT90% (r Z 0.3; p Z 0.05) in the OSAS
patients were also directly correlated with FENO. The OSAS
smokers had lower FENO levels than non-smokers
(12  6 ppb vs 35  4 ppb, respectively; p Z 0.01).
CANO levels were significantly lower in the OSAS group
than in the healthy (non-OSAS) group (Table 2). The OSAS
smokers had lower CANO levels than non-smokers but the
difference was not statistically significant (1.2  0.6 ppb vs
1.6  0.6 ppb, respectively; p Z 0.2). There was a signifi-
cant negative correlation between the mean CANO level and
AHI, (r Z 0.9, p Z 0.01) (Fig. 1). CANO levels and mean
nighttime SpO2 (r Z 0.5, p Z 0.02) (Fig. 2) and CT90%
(rZ 0.5, pZ 0.03) were also significantly correlated. We
also observed a significant negative correlation between
FENO and CANO levels in the OSAS group (rZ 0.7, pZ 0.01)
while in the healthy (non-OSAS) group the correlation was
significant but weak (r Z 0.4, p Z 0.025). CANO levels didTable 2 Nitric oxide measurements in OSAS patients, before an
OSAS group
n Z 30
Healthy Non-O
group n Z 30
FENO ppb, mean  SD 27.2  18 16.7  8
DAWNO, ml/s, mean (95% CI) 24.8 (2.4e169) 4.8 (0.5e10.4)
J’AW,NO, pl/s, mean (95% CI) 1147 (53.6e5800) 566 (113e1755
CANO, ppb, mean  SD 1.65  0.90 2.86  1.39
Data are presented as mean  SD or followed by the 95% confide
syndrome; CPAP: continuous positive airway pressure; FENO: fraction o
capacity; J’AWNO: maximum total airway nitric oxide flow; CANO: alveonot correlate with sex, age, BMI, or respiratory function
status (p > 0.05).
The multiple logistic regression model confirmed that
two variables, the presence of a diagnosis of OSAS
(r Z 0.508, p Z 0.006) and severity (AHI, r Z 0.9, p Z
0.001) remained significantly associated with CANO level
independently of age, sex, weight and BMI. Both these
variables also remained significantly associated with FENO in
the model (OSAS diagnosis: r Z 0.8, p Z 0.005; AHI: r Z
0.6, p Z 0.001).
FENO and CANO measurements after CPAP treatment
CPAP treatment was initiated in 24 of the 30 OSAS patients.
At the 3-month follow-up visit, CPAP was being used for
a mean of 6  1 h per night. At which time FENO levels had
decreased significantly (Fig. 3). Because two outliers were
present,we compared FENO levels before and after CPAPwith
a nonparametric Wilcoxon test (even though the Kolmogor-
oveSmirnov test showed that the data were normally
distributed). The decrease in FENO after treatment remained
statistically significant (pZ 0.018) in that comparison.
CANO levels, however, had increased significantly by
2.9  1 ppb (Fig. 4). There was a weak but significant
correlation between the change in CANO level and the AHI at
diagnosis (r Z 0.4; p Z 0.04), (Table 2).d after CPAP treatment, and in the non-OSAS group.
SAS p-value CPAP, OSAS group n Z 24 p-value
Pre-CPAP Post-CPAP
0.006 31.5  18 20  10 0.018
0.005 27.3 (2.4e169) 8.9 (0.1e82) 0.01
) 0.004 1255 (54e5802) 1112 (14e7500) 0.49
0.001 1.8  0.8 4.2  1.6 0.01
nce interval (CI), as indicated. OSAS: obstructive sleep apnoea
f exhaled breath nitric oxide; DAW,NO: nitric oxide airway diffusing
lar nitric oxide concentration.
Figure 1 Correlation between alveolar nitric oxide (CANO)
level and the apneaehypopnea index (AHI) in patients with
obstructive sleep apnea syndrome (r Z 0.9; p Z 0.01).
Figure 2 Correlation between alveolar nitric oxide (CANO)
levels and mean nighttime arterial oxygen saturation (SpO2%)
(r Z 0.5; p Z 0.02) in patients with obstructive sleep apnea
syndrome.
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Figure 3 Lines graph showing individual levels of exhaled
nitric oxide (FENO) before and after continuous positive airway
pressure (CPAP) treatment of 24 patients with obstructive
sleep apnea syndrome. Mean value is included.
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Our study confirmed that OSAS patients have FENO levels
that are higher than those of healthy (non-OSAS) individ-
uals, consistent with the presence of an upper airway
inflammatory process. We also confirmed that FENO level
was correlated with OSAS severity. In addition, CANO levels
were lower in OSAS patients and this measure was also
correlated with OSAS severity, suggesting that these
patients have abnormal NO bioavailability that would lead
to endothelial dysfunction. CPAP treatment improved and
restored the FENO and CANO levels after 3 months of treat-
ment in the 24 treated patients.
Higher levels of FENO in OSAS patients reflect the pres-
ence of bronchial and upper airway inflammation. Elevated
levels of polymorphonuclear cells and inflammatory medi-
ators in the nasal mucosa of OSAS patients were described
by Hatipoglu and Rubinstein.30 They also observed the
presence of subepithelial edema, a reduction in connective
tissue, and inflammatory cell infiltration of pharyngeal
tissue obtained by uvulopalatopharyngoplasty or tonsillec-
tomy. The transfer of the pharyngeal pressure gradient
toward the lower airway and the effect of proinflammatory
cytokines also favor the development of bronchial5,6
7
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Figure 4 Lines graph showing individual values levels of
alveolar nitric oxide (CANO) before and after continuous posi-
tive airway pressure (CPAP) treatment of 24 patients with
obstructive sleep apnea syndrome. Mean value is included.
Abbreviations
AHI´ apnea-hypopnea index
BMI body mass index
CANO alveolar nitric oxide
CPAP continuous positive airway pressure
CT90% the cumulative time with SpO2 < 90%
DAWNO airway diffusion
FENO airway nitric oxide
FEV1 forced expiratory volume in 1 s
FVC forced vital capacity
J’AW NO maximum total airway NO flow
NO nitric oxide
OSAS obstructive sleep apnea syndrome
ppb parts per billion
SpO2 arterial oxygen saturation
VE exhaled constant flow rate
VNO exhaled NO flow rate
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obtained by noninvasive techniques (induced sputum or
exhaled breath condensate, for example).17 Salerno et al31
and Devaousassaux et al32 observed neutrophil predomi-
nance and macrophage deficits in the induced sputum of
OSAS patients compared with healthy individuals. The
higher levels of FENO and J’AWNO we observed in OSAS
patients in this study are consistent with the work of other
groups studying inflammatory markers in exhaled
breath.17,31,33 The correlation we observed between FENO
levels and OSAS severity as demonstrated by the AHI and
nighttime desaturation also reflects greater upper airway
inflammation in patients with more severe OSAS. This level
of inflammation would contribute to worsening OSAS by
narrowing the upper airway, as was demonstrated by Culla
et al34 recently. Those authors showed that severe OSAS
patients present an increased oral NO, suggesting that oral
inflammation in OSA patients could be a consequence of
intermittent hypoxia.
Our smoking patients had lower FENO and CANO levels than
ex-smokers and non-smokers. Cigarettes contain a large
number of free radicals and pro-oxidant substances which
cause lower NO bioactivity and favor an oxidative stress
state. In addition, smokers have a tetrahydrobiopterin
deficit; this cofactor is necessary for the process by which
endothelial NO is generated.35
In our study OSAS patients also had lower CANO levels than
individuals in the non-OSAS group, suggesting the presence
of endothelial dysfunction in the former. Endothelial NO is
the main factor implicated in endothelium-dependent
vasodilation and its synthesis depends on the balance
between oxygen-free radical production and degradation
and NO production.7 In OSAS the increased release of
oxygen-free radicals induced by hypoxia-reoxygenation
exceeds physiological antioxidation, favoring a reduction in
cofactors required for NO synthesis and greater synthesis of
the superoxide radical and peroxynitrite.7,8 Hypoxia also
alters the production of endothelial NO synthase, favoring
lower levels of circulating NO in these patients,13 with
a deleterious effect on the vascular bed. A more direct,
noninvasive way to measure the availability of endothelial
NO and therefore of assessing possible endothelial dysfunc-
tion would be the measurement of CANO. This marker
depends on the concentration in the alveolus and its diffu-
sion through the alveolar-capillary membrane, so that if NO
synthesis is decreased, less will be diffused and exhaled.15
The low CANO levels in our OSAS group are consistent with
the only study that analyses CANO in such patients.
18 Foresi et
al showed that CANO values were significantly lower in OSAS
patients with systemic hypertension compared to those of
non-hypertensive OSAS patients, and the authors conclude
that their findings may be linked to a possible endothelial
dysfunction in OSAS patients.18 We additionally found that
CANO levels correlated with OSAS severity, with lower SpO2
and increased CT90%. In addition, CANO and FENO levels were
correlated with each other, so that those with more upper
airway and bronchial inflammation had more endothelial
dysfunction, and these patients were also precisely the ones
who had more severe OSAS.
Physiologic FENO and CANO levels were restored after 3
months of CPAP treatment. Moreover, the group of patients
with more severe disease presented more marked changewhen their normal CANO levels were reestablished. Whether
or not to treat patients with CPAP only on the basis of AHI is
debated, particularly in patients with severe nonsleepy
OSAS.20 In such cases biomarkers such as FENO and CANO
obtained by noninvasive measurements could eventually to
provide valuable molecular signatures in OSAS.36
A limitation of this study is that there are statistically
significant differences in anthropometric parameters, such
as BMI, between the OSAS group and the healthy individuals
whose NO data were used for comparison. We know that
obesity itself favors inflammation and oxidative stress that
predisposes the individual to metabolic syndrome and
OSAS.36 However, the results for FENO and obesity are
inconsistent in the literature. Depalo et al16 demonstrated
higher FENO levels and increased neutrophils in the induced
sputum of obese OSAS patients in comparison with obese
non-OSAS individuals. However Petrosyan et al17 saw no
significant differences in FENO between these two types of
patient. In our study we found no correlation between BMI
and either FENO level or CANO level either in OSAS patients or
non-OSAS individuals, consistent with the findings of Foresi
et al.18 These results are also consistent with recent litera-
ture showing that OSA is a major determinant of endothelial
dysfunction independently of obesity.37 Furthermore,
logistic regression showed that the presence of OSAS and
severity as shown by AHI are the only factors that remained
correlated with FENO and CANO levels in the multiple regres-
sion model to rule out covariation with age, sex or BMI.
Finally, the most important finding of our study, the change
in FENO and CANO levels after 3 months of CPAP treatment,
was found by analyzing within-subject differences before
and after CPAP treatment, a strength of our study.
In conclusion, severe OSAS patients have higher FENO and
lower CANO levels compared to healthy patients, and phys-
iologic levels are restored after 3 months of CPAP treat-
ment. Exhaled breath techniques to measure airway and
endothelial NO provide an easy, noninvasive way to detect
or monitor local upper airway inflammation and endothelial
dysfunction in severe OSAS patients. Use of these measures
would contribute to, aiding more accurate prediction of
response to treatment.
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